In Situ Hybridization in Clinical Biomarker Development
- Usha SinghAffiliated withTranslational Medicine, Merck & Co. Email author
- , Marisa Dolled-FilhartAffiliated withTranslational Medicine, Merck & Co.
- , Dianna WuAffiliated withTranslational Medicine, Merck & Co.
Biomarkers are being utilized from early to clinical phases of drug development. Nucleic acid-based biomarkers have proven their significance in predicting disease occurrence, identifying the reason for variable drug responses and helping in personalized targeted therapy. There are various techniques available for analyzing nucleic acid-based biomarkers in body fluids and in tissue homogenates; however, detection of tissue-based biomarkers in the context of tissue/cell morphology is still limited to the use of in situ hybridization (ISH) technology. This book chapter provides an overview of available ISH technologies, efforts made toward the advancement of ISH to increase the sensitivity and specificity of assays and their applications in clinical biomarker.
- In Situ Hybridization in Clinical Biomarker Development
- Book Title
- Translating Molecular Biomarkers into Clinical Assays
- Book Subtitle
- Techniques and Applications
- pp 201-210
- Print ISBN
- Online ISBN
- Series Title
- AAPS Advances in the Pharmaceutical Sciences Series
- Series Volume
- Series ISSN
- Springer International Publishing
- Copyright Holder
- American Association of Pharmaceutical Scientists
- Additional Links
- Industry Sectors
- eBook Packages
- Editor Affiliations
- 3. Translational Biomarkers and Personalized Medicine
- 4. MKelley Consulting LLC
- Author Affiliations
- 5. Translational Medicine, Merck & Co., 126 East Lincoln Ave, Rahway, NJ, 07065, USA
To view the rest of this content please follow the download PDF link above.